PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment - Seite 2

Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, said "we are pleased and excited that we have completed enrolment of this large trial. Between ATLANTIS and our monotherapy trial, we hope to deliver to regulators data sets that can lead to the approval of Lurbinectedin for this difficult to treat disease."

About PharmaMar   

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS^® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre^® (lurbinectedin, PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.

About Zepsyre^{[® ]}

Zepsyre^® (lurbinectedin, PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

About small-cell lung cancer   

SCLC is a very aggressive cancer that usually presents with distant metastases and has already spread at the time of diagnosis, thus limiting the role of traditional approaches and posing a worse prognosis compared to other lung cancer types. The 5-year survival rate is about 5%^[i]. About 18% of all the lung cancer cases diagnosed are SCLC, and only in the US more than 34,000 new cases are recorded every year. This tumor is strongly associated with tobacco smoking, posing an important public health problem^[ii]. After failure to treatment with a platinum-based therapy in first line, the therapeutic alternatives are very limited, and the approval of the last drug for this disease took place 20 years ago.

Disclaimer  

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

^[i] http://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq
^[ii] http://www.jnccn.org/content/11/1/78.full.pdf

Media Contact:  

Alfonso Ortín - Communications Director [e-mail] Mobile: [phone]
Miguel Martínez-Cava - Digital Communication Manager [e-mail] Mobile: [phone]
Phone: [phone]

Investor Relations: 
Phone: [phone]

Or please visit our website at http://www.pharmamar.com